NT-proBNP, ST2, and galectin-3 correlated with reduced left ventricular ejection fraction in breast cancer patients receiving anthracyclines (baseline NT-proBNP ρ = -0.45; p=0.019).
Cohort (n=31)
Do cardiac biomarkers and strain echocardiography correlate with subclinical cardiotoxicity in breast cancer patients receiving anthracyclines?
Cardiac biomarkers including NT-proBNP, ST2, and galectin-3 correlate with reduced LVEF and subclinical cardiotoxicity in breast cancer patients receiving anthracycline therapy.
Effect estimate: ρ = -0.45
p-value: p=0.019
The optimal surveillance and management strategies for breast cancer patients receiving anthracycline therapy are limited by our incomplete understanding of the role of biomarkers heralding the onset of cardiotoxicity. The purpose of this study was to determine whether there is a temporal correlation between cardiac biomarkers and subclinical left ventricular dysfunction in breast cancer patients receiving anthracycline chemotherapy. Thirty-one females between 46 and 55 years old with breast cancer treated with anthracycline chemotherapy were prospectively enrolled. Cardiac biomarkers were correlated with echocardiography with speckle tracking at baseline, post-anthracycline therapy, and 6 months post-anthracycline chemotherapy. Subclinical cardiotoxicity was defined as ≥ 10% reduction in global longitudinal strain (GLS). There was a relative reduction in left ventricular ejection fraction (LVEF) ≥ 10% in 5/30 (17%) and 7/27 (26%) patients post-anthracycline therapy and 6 months post-anthracycline therapy, respectively. Subclinical cardiotoxicity was noted in 8/30 (27%) and 10/26 (38%) patients post-anthracycline and 6 months post-anthracycline therapy, respectively. Baseline N-terminal pro B-type natriuretic peptide (NT-proBNP) was the strongest predictor of LVEF (ρ = −0.45; p = 0.019), with post-therapy NT-proBNP values illustrating similar predictive value (ρ = −0.40; p = 0.038). Interim changes in suppression of tumorigenicity 2 (ST2) and galectin-3 correlated with a 6-month change in LVEF (ρ = −0.48; p = 0.012 and ρ = −0.45; p = 0.018, for ST2 and galectin-3, respectively). Changes in galectin-3 from baseline to mid-therapy paralleled changes in GLS. NT-proBNP, ST2, and galectin-3 correlate with reduced LVEF among breast cancer patients receiving anthracycline therapy. Additional trials focusing on a cardiac biomarker approach may provide guidance in the early diagnosis and management of anthracycline-induced cardiotoxicity.
Bhagat et al. (Thu,) conducted a cohort in Breast cancer (n=31). Cardiac biomarkers (NT-proBNP, ST2, galectin-3) was evaluated on Temporal correlation between cardiac biomarkers and subclinical left ventricular dysfunction (ρ = -0.45, p=0.019). NT-proBNP, ST2, and galectin-3 correlated with reduced left ventricular ejection fraction in breast cancer patients receiving anthracyclines (baseline NT-proBNP ρ = -0.45; p=0.019).